have a crucial role is new drug development. Drug development has been changed in last two decades because massive progresses in molecular biology have been made that is leading to detailed understanding of the genetic abnormalities in different diseases. The advancements in offer the opportunity of using imaging biomarkers to fasten the drug development process.
can be Anatomical, functional and molecular characterized and these anatomical could be the only imaging surrogate endpoints that can be accepted in cancer treatment. target-specific. Functional imaging biomarkers have the advantage of being downstream markers that probe general capabilities of disease, including cell death, proliferation, glycolysis, tumor invasiveness, angiogenesis, inflammation, fibrosis and they are used as .